How Recent 340B Changes Impact Specialty Pharmacies In 2025

June 4, 2025340B, Compliance, Covered Entities, Drug Manufacturer Restrictions, News Updates, Readmissions Reduction, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s a breakdown of the new developments and their likely impacts: Recent 340B changes and their impact on specialty pharmacies 1. 340B contract pharmacy restrictions Drug manufacturers have increasingly restricted the use of contract pharmacies, especially … Read More

How To Use Your 340B Program As a Community Health Engine

May 13, 2025340B, PBM, Prescription Discounts, Readmissions Reduction, Retail / Outpatient Pharmacy, Specialty Drugs, Value-Based Care

The 340B Drug Pricing Program, established by Congress in 1992, was designed to enable eligible healthcare organizations to stretch scarce federal resources, reaching more eligible patients and providing more comprehensive services. Over the years, this program has evolved into a powerful tool that can significantly enhance a hospital’s ability to improve patient outcomes, and ensure … Read More

The Pharmacy Model That Restores Control To 340B Hospitals

January 24, 2025340B, Drug Manufacturer Restrictions, Prescription Discounts, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

How your health system can leverage visibility, your PBM and your pharmacies to achieve your financial and clinical goals.   The systemic problem: Overview The U.S. prescription drug market is a textbook case of waste and inefficiency — one that, in recent years, has disproportionately benefited a handful powerful corporations at the expense of providers, … Read More

So You Want To Build A 340B Specialty Pharmacy. How Hard Can It Be?

December 30, 2024340B, Covered Entities, Drug Manufacturer Restrictions, Specialty Drugs, Specialty Pharmacy

Fair Warning: If you ever dismissively ask that question (above) of someone who’s led the planning and launch of a 340B hospital’s specialty pharmacy, and did it with no outside support, there’s a good chance you’ll get punched. Yes, it’s that difficult.   POST OUTLINE Why is it so hard to build a 340B specialty … Read More

340B Outlook For 2024: Change. Change. And More Change.

April 19, 2024340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

POST OUTLINE 1) What we’ve learned. What it means for your 340B program. Overview of ProxsysRx 340B Team experience and successes Dealing with frequent, unexpected changes 2) Potential 340B developments for 2024 National legislation prospects State regulatory changes 3) Legislative & court updates Bill introduced into House Of Representatives Supreme Court overturns 340B restriction cuts … Read More

The Case for Onsite Specialty Pharmacies in 340B Hospitals

April 4, 2024340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Prescription Discounts, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More

Best Practices For A 340B Hospital Looking To Build An Onsite Specialty Pharmacy

March 28, 2024340B, Outpatient Tracking, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

ProxsysRx recently gathered three of its corporate executives for an in-depth discussion of how an eligible health system can optimize revenues from its 340B program and its retail pharmacy, to help build and fund an onsite specialty pharmacy. Below is a lightly-edited transcript of that discussion. NOTE: If you’d prefer to watch the complete video … Read More

Partnering With Manufacturers To Overcome 340B Specialty Drug Restrictions

March 1, 2024340B, 340B ESP, Bedside Prescription Delivery, Drug Manufacturer Restrictions, Medicare, Meds To Beds, PBM, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

It’s no secret that the 340B Drug Pricing Program has been a lifeline for eligible health systems, enabling them to fill-in the massive revenue gaps inherent to the non-profit-hospital business model (and, in the process, support their mission of providing quality care to our nation’s most vulnerable patients) through access to discounted prescription refills. At … Read More

Your Hospital’s 340B Contract Pharmacy Network Is Not What It Should Be.

February 15, 2024340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Patient Eligibility, PBM, Prescription Discounts, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs, Uncategorized

Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 21 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More

Leveraging Partnerships With Drug Manufacturers To Overcome 340B Restrictions On Specialty Drugs

October 26, 2023340B, 340B ESP, Bedside Prescription Delivery, Drug Manufacturer Restrictions, Medicare, Meds To Beds, PBM, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

Since the advent of 340B ESP in 2020, drug manufacturers have imposed a raft of unlawful restrictions on 340B program savings. Nowhere have those restrictions been more punitive than with specialty pharmacy medications; drugs which typically represent the most expensive (and profitable) in manufacturers’ product lines. 340B restrictions from the drug manufacturers’ perspective That said, … Read More